Market Overview

Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progress

Share:

OXFORD, United Kingdom, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD') and C. difficile infection (‘CDI'), today reports its financial results for the second quarter and half year ended 31 July 2017.

Mr Glyn Edwards, Chief Executive Officer of Summit, commented: "It has been a strong first half of the year with progress being made across all areas of the business. Ezutromid, our lead utrophin modulator for DMD, achieved an important development milestone following completion of enrolment into our clinical trial called PhaseOut DMD, triggering a $22 million payment from our licence and collaboration partner Sarepta Therapeutics. PhaseOut DMD aims to show proof of concept for ezutromid, and we look forward to reporting 24-week data from the trial in the first quarter of 2018.

"Ridinilazole, our highly selective and potent antibiotic for the treatment of C. difficile infection, also continues to progress as we prepare the asset to start Phase 3 clinical trials in the first half of 2018.  We believe ridinilazole can become a new, urgently needed frontline therapy for this serious infectious disease.

"We look forward to an exciting and important period ahead as we continue advancing these two assets that have the potential to improve the quality of life of patients and families living with DMD and CDI."

Utrophin Modulation Programme for DMD

Ezutromid - Highlights

  • Completed enrolment into PhaseOut DMD in May 2017, which triggered a $22.0 million development milestone payment as part of Summit's licence and collaboration agreement with Sarepta Therapeutics, Inc (‘Sarepta'). PhaseOut DMD is a 48-week, open label Phase 2 clinical trial that has enrolled 40 patients at sites in the UK and US. The trial aims to establish proof of concept of ezutromid and is evaluating a range of muscle structure, muscle health and functional endpoints.
  • Expecting to report full 24-week data analysis from PhaseOut DMD in Q1 2018. This data set will include 24-week biopsy data from all patients who provide a 24-week biopsy sample (approximately 20 patients). In addition, Summit expects to report 24-week MRI and functional data from all 40 patients in the trial. Top-line data from the complete 48-week clinical trial are expected in Q3 2018.

CDI Programme

Ridinilazole - Highlights

  • Presented preclinical data at ASM Microbe 2017, including data showing that ridinilazole was very active against all 200 clinical isolates of C. difficile and was more potent than the marketed broad-spectrum antibiotics vancomycin and metronidazole. In addition, it was reported that a low-level, stable ridinilazole mutant resistant strain was developed to help further elucidate ridinilazole's mechanism of action.
  • Exploring various funding options for the Phase 3 development programme as the Company seeks to maximize the value of ridinilazole. These possible options include entering into a collaboration with a third party and/or securing meaningful non-dilutive funding from government entities and philanthropic, non-government and not for profit organisations.
  • Planning to report data from an exploratory Phase 2 clinical trial evaluating ridinilazole against the antibiotic fidaxomicin later this year. A key objective of the trial is to determine the relative impact on the patients' microbiomes following treatment with ridinilazole compared to fidaxomicin.

Operational Highlights

  • Strengthened R&D team with Chief Operating Officer Dr David Roblin expanding his role to include serving as Chief Medical Officer and the appointments of Dr Anne Heatherington as Head of Clinical Development & Quantitative Sciences and Dr Dave Powell as Head of Research. These appointments, announced in May 2017, will help ensure the Company has the leadership, depth of knowledge and expertise needed to support its clinical and preclinical pipeline.

Financial Highlights

  • Cash and cash equivalents at 31 July 2017 of £28.3 million compared to £28.1 million at 31 January 2017.
  • Cash balance at 31 July 2017 reflects receipt of $22.0 million (£17.2 million) development milestone payment from Sarepta during the three months ended 31 July 2017.
  • Profit for the six months ended 31 July 2017 of £6.2 million compared to a loss of £11.9 million for the six months ended 31 July 2016 (adjusted).

Conference Call and Webcast Information
Summit will host a conference call and webcast to review the financial results for the second quarter and half year ended 31 July 2017 today at 1:00pm BST / 8:00am EDT. To participate in the conference call, please dial +44(0)20 3427 1916 (UK and international participants) or +1 212 444 0412 (US local number) and use the conference confirmation code 9691365. Investors may also access a live audio webcast of the call via the investors section of the Company's website www.summitplc.com. A replay of the webcast will be available shortly after the completion of the call.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)
Tel: +44 (0)1235 443 951
  +1 617 225 4455
   
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson


Tel: +44 (0)20 7213 0880
   
N+1 Singer
(Broker)
Aubrey Powell / Lauren Kettle 
Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications
(US media contact)
Karen Sharma
Tel: +1 781 235 3060
ksharma@macbiocom.com

   
Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Jessica Hodgson /
Philippa Gardner / Rosie Philips
Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements about the development and potential commercialisation of our product candidates, the therapeutic potential of our product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential benefits and future operation of the collaboration with Sarepta including any potential future payments thereunder, any other potential third-party collaborations and expectations regarding the sufficiency of our cash balance to fund operating expenses and capital expenditures, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that we make with the Securities and Exchange Commission, including our Annual Report on Form 20-F for the fiscal year ended 31 January 2017. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

FINANCIAL REVIEW

Revenue

Revenue was £18.9 million for the three months ended 31 July 2017 compared to £nil for the three months ended 31 July 2016. Revenue was £20.7 million for the six months ended 31 July 2017 compared to £nil for the six months ended 31 July 2016. These increases were principally due to the receipt, and recognition in full, of a £17.2 million ($22.0 million) development milestone paid by Sarepta during the three months ended 31 July 2017, pursuant to Summit's exclusive licence and collaboration agreement with Sarepta. In addition, £1.7 million relating to the upfront payment of £32.8 million ($40.0 million) made by Sarepta in October 2016 was recognised in the three months ended 31 July 2017. To date an aggregate of £5.8 million of the upfront payment has been recognised while the remaining £27.0 million is classified as deferred revenue and will continue to be recognised as revenue over the development period.

Other Operating Income

There were no sources of other operating income during the three and six months ended 31 July 2017. Operating income recognised in comparative periods relates to the Innovate UK funding agreement, from which the Company withdrew in order to enable it to take advantage of more tax efficient opportunities related to research and development expenditure, and the Wellcome Trust funding agreement, for which all monies and income have been received and accounted for in connection with the completion of our CoDIFy Phase 2 clinical trial of ridinilazole.

Operating Expenses

Research and Development Expenses
Research and development expenses increased by £1.2 million to £6.6 million for the three months ended 31 July 2017 from £5.4 million for the three months ended 31 July 2016. Research and development expenses increased by £1.4 million to £11.6 million for the six months ended 31 July 2017 from £10.2 million for the six months ended 31 July 2016. These increases reflected the increased investment in the DMD programme and an increase in research and development related staffing costs, offset by a decrease in CDI clinical programme related activities.  

General and Administration Expenses
General and administration expenses increased by £0.6 million to £2.5 million for the three months ended 31 July 2017 from £1.9 million for the three months ended 31 July 2016. General and administration expenses increased by £1.6 million to £4.9 million for the six months ended 31 July 2017 from £3.3 million for the six months ended 31 July 2016. These increases were primarily due to a net negative movement in exchange rate variances and increased staff-related costs, offset by a decrease in legal and professional fees.

Finance Costs
Following an International Financial Reporting Standards Interpretations Committee agenda decision in May 2016 on the application of International Accounting Standards 20 'Accounting for Government Grants and Disclosure of Government Assistance', the Company changed its accounting policy regarding charitable funding arrangements from the Wellcome Trust and US not for profit organisations for the year ended 31 January 2017. See Note 1 – ‘Change in accounting policy in respect of July 2016 comparatives' below. This change in accounting policy has been reflected retrospectively in the comparative financial statements for the three and six months ended 31 July 2016. Finance costs relate to the subsequent re-measurement of the financial liability recognised in respect of income arrangements and the unwinding of the discounts associated with the liabilities. Finance costs remained consistent at £0.2 million for the three months ended 31 July 2017 and for the three months ended 31 July 2016 (adjusted). Finance costs remained consistent at £0.4 million for the six months ended 31 July 2017 and for the six months ended 31 July 2016 (adjusted).

Taxation

The income tax credit increased by £0.2 million to £1.3 million for the three months ended 31 July 2017 from £1.1 million for the three months ended 31 July 2016. The income tax credit increased by £0.5 million to £2.5 million for the six months ended 31 July 2017 from £2.0 million for the six months ended 31 July 2016. These increases were as a result of increased expenditure on research and development.

Profit / (Loss)

Total comprehensive income for the three months ended 31 July 2017 was £10.9 million with a basic earnings per share of 18 pence compared to a total comprehensive loss of £6.4 million for the three months ended 31 July 2016 (adjusted) and a basic loss per share of 10 pence. Total comprehensive income for the six months ended 31 July 2017 was £6.2 million with a basic earnings per share of 10 pence compared to a total comprehensive loss of £11.8 million for the six months ended 31 July 2016 (adjusted) and a basic loss per share of 19 pence.

Cash Flows

Operating Activities
For the six months ended 31 July 2017, the Company generated £1.5 million in cash from operating activities. This compares to net cash used in operating activities of £9.5 million for the six months ended 31 July 2016 (adjusted). This net movement of £11.0 million was primarily driven by the receipt of a £17.2 million ($22.0 million) development milestone payment from Sarepta, offset by an increase of £3.0 million in research and development expenses and general and administration expenses and a decrease of £3.1 million in research and development tax credits received due to timing, as the Company expects to receive this year's research and development tax credit payment in the next quarter.

Investing Activities
Net cash used in investing activities for the six months ended 31 July 2017 and the six months ended 31 July 2016 includes the net amount of bank interest received on cash deposits less amounts paid to acquire property, plant and equipment. Amounts paid to acquire property, plant and equipment during the six months ended 31 July 2017 relate to the Company's relocation of its UK offices, for which the Company signed a ten-year lease in February 2017.

Financing Activities
Net cash inflow from financing activities for the six months ended 31 July 2017 relates to proceeds of £0.03 million received following the exercise of warrants and the exercise of share options. For the six months ended 31 July 2016, the Company received net proceeds of £0.11 million following the exercise of warrants and share options.

Financial Position

As at 31 July 2017, cash and cash equivalents were £28.3 million compared to £28.1 million as at 31 January 2017.

Glyn Edwards                           Erik Ostrowski
Chief Executive Officer             Chief Financial Officer

31 August 2017


FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (unaudited)
For the three months ended 31 July 2017
   

 
Three
months
ended
31 July
2017

Three
months
ended
31 July
2017
Three
months
ended
31 July
2016
Adjusted*
  Note $000s £000s £000s
         
Revenue 2 25,009   18,952   -  
         
Other operating income   -   -   13  
         
Operating expenses        
  Research and development   (8,720 ) (6,608 ) (5,399 )
  General and administration   (3,284 ) (2,488 ) (1,910 )
Total operating expenses   (12,004 ) (9,096 ) (7,309 )
         
Operating profit / (loss)   13,005   9,856   (7,296 )
         
Finance income   1   1   2  
Finance costs   (289 ) (219 ) (210 )
         
Profit / (loss) before income tax   12,717   9,638   (7,504 )
         
Income tax   1,693   1,283   1,076  
         
               
Profit / (loss) for the period  
View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com